CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531

PURPOSE: Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjugate, is a re-emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide polymorphism rs12459419 C>T in the splice enhancer region regulates the expression of an alternatively spliced CD33 isoform lacking exon2 (D2-CD3...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Lamba, Jatinder K., Chauhan, Lata, Shin, Miyoung, Loken, Michael R., Pollard, Jessica A., Wang, Yi-Cheng, Ries, Rhonda E., Aplenc, Richard, Hirsch, Betsy A., Raimondi, Susana C., Walter, Roland B., Bernstein, Irwin D., Gamis, Alan S., Alonzo, Todd A., Meshinchi, Soheil
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5549451/
https://ncbi.nlm.nih.gov/pubmed/28644774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.71.2513
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados